文献速递产科母胎医学

评估围产期毒理学检测的临床效用

Assessing the clinical utility of toxicology testing in the peripartum period.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-04-07

本研究回顾性分析了马萨诸塞州单家医疗系统2016至2020年间2036例分娩时接受母婴毒理学检测的母婴对,其中80例(3.9%)出现意外阳性结果。以近2年物质使用障碍活跃使用为检测理由时意外阳性率最高(10.7%)。意外阳性后42%转介儿童保护服务,产后仅32.5%完成产后访视,18.8%因物质相关医疗并发症再入院。

要点

  • 分娩时毒理学检测意外阳性结果不常见,总体为3.9%。
  • 近2年物质使用障碍活跃使用为检测理由时意外阳性率最高,达10.7%。
  • 意外阳性后42%转介儿童保护服务,产后仅32.5%完成产后访视。

核心结论

  • 分娩时意外阳性毒理学结果不常见,尤其当检测基于常用临床理由时,提示需重新审视毒理学检测适应症适当性的指南。
  • 该队列孕产妇结局不良,凸显围产期孕产妇连接咨询和治疗的机会 missed。

研究设计与样本

  • 回顾性病历审查,纳入马萨诸塞州单家医疗系统2016至2020年间所有分娩,识别分娩时接受孕产妇或新生儿毒理学检测的分娩。
  • 共2036例母婴对接受毒理学检测。
  • 意外阳性结果定义为:检测出非处方物质阳性,且根据临床病史、自我报告或分娩前一周内既往毒理学检测未知,排除大麻结果。

主要发现

  • 2036例母婴对中,80例(3.9%)出现意外阳性结果。
  • 近2年物质使用障碍活跃使用为检测理由时意外阳性率最高(占该理由总检测的10.7%)。
  • 产前保健不足(5.8%)、孕产妇使用阿片类物质使用障碍药物(3.8%)、孕产妇医学指征如高血压或胎盘早剥(2.3%)、物质使用障碍缓解期病史(1.7%)或孕产妇大麻使用(1.6%)的意外阳性率低于近2年物质使用障碍。
  • 仅基于意外检测结果,42%母婴对转介儿童保护服务,30%在分娩住院期间无孕产妇咨询记录,31%在意外检测后未接受母乳喂养咨询;22.8%接受新生儿阿片戒断综合征监测。
  • 产后,26例(32.5%)转介物质使用障碍治疗,31例(38.8%)参加产后心理健康访视,仅26例(32.5%)参加产后访视。

临床怎么用

  • 作者认为需重新审视围产期毒理学检测适应症适当性的指南。
  • 作者指出该队列孕产妇结局不良,凸显围产期孕产妇连接咨询和治疗的机会 missed。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Toxicology testing is frequently used as a means of gathering objective data about substance use in pregnancy, but little is known about the clinical utility of testing in the peripartum setting. OBJECTIVE: This study aimed to characterize the utility of obtaining maternal-neonatal dyad toxicology testing at the time of delivery. STUDY DESIGN: We performed a retrospective chart review of all deliveries in a single healthcare system in Massachusetts between 2016 and 2020, and identified deliveries with either maternal or neonatal toxicology testing at delivery. An unexpected result was defined as a positive test for a nonprescribed substance that was not known on the basis of clinical history, self-report, or previous toxicology testing within a week of delivery, excluding results for cannabis. We evaluated the characteristics of maternal-infant dyads with unexpected positive results, unexpected positive results by rationale for testing, changes in clinical management after an unexpected positive test, and maternal outcomes in the year after delivery using descriptive statistics. RESULTS: Of the 2036 maternal-infant dyads with toxicology tests performed during the study period, there were 80 (3.9%) with an unexpected positive result. Diagnosis of substance use disorder with active use in the last 2 years was the clinical rationale for testing that yielded the greatest number of unexpected positive results (10.7% of total tests ordered for this rationale). Inadequate prenatal care (5.8%), maternal use of medication for opioid use disorder (3.8%), maternal medical indications such as hypertension or placental abruption (2.3%), history of substance use disorder in remission (1.7%), or maternal cannabis use (1.6%) yielded lower rates of unexpected results compared with a recent substance use disorder (within the last 2 years). Solely on the basis of findings from unexpected test results, 42% of dyads were referred to child protective services, 30% of dyads had no documentation of maternal counseling during delivery hospitalization, and 31% did not receive breastfeeding counseling after an unexpected test; 22.8% had monitoring for neonatal opioid withdrawal syndrome. Postpartum, 26 (32.5%) were referred to substance use disorder treatment, 31 (38.8%) attended a postpartum mental health visit, and only 26 (32.5%) attended a postpartum visit. Fifteen individuals (18.8%) were readmitted in the year after delivery, all for substance-related medical complications. CONCLUSION: Unexpected positive toxicology results at delivery were uncommon, particularly when tests were sent for frequently used clinical rationales for testing, suggesting a need to revisit guidelines surrounding appropriateness of indications for toxicology testing. The poor maternal outcomes in this cohort highlight a missed opportunity for maternal connection to counseling and treatment in the peripartum period.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Siegel MR, Cohen SJ, Koenigs K, et al. Assessing the clinical utility of toxicology testing in the peripartum period. Am J Obstet Gynecol MFM. 2023. PMID: 37030508. doi:10.1016/j.ajogmf.2023.100963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。